8-K: Celcuity Launches $225M Concurrent Offering of Convertible Notes and Common Stock, Amends Loan Agreement

Celcuity Inc. announced a proposed concurrent public offering to raise $225 million through convertible senior notes and common stock, alongside an amendment to its loan agreement to facilitate the offering and allow for an additional $30 million debt draw.

Summary

• Celcuity Inc. launched a proposed concurrent offering to issue and sell $150.0 million aggregate principal amount of Convertible Senior Notes due 2031.
• The company also proposes to sell $75.0 million of shares of its common stock in a concurrent offering.
• Underwriters will have a 30-day option to purchase an additional $22.5 million in Convertible Notes and $11.25 million in common stock to cover over-allotments.
• The company entered into a Second Amendment to its Amended and Restated Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP and Oxford Finance LLC.
• The Second Amendment permits the issuance of the Notes and related transactions, including conversion settled solely in common stock (plus cash for fractional shares).
• It also permits capped call transactions expected in connection with the Notes pricing.
• An amendment fee of $25,000 was paid to Oxford Finance LLC.
• Innovatus's right to convert up to 20% of the Term A Loan principal into common stock at $10.00 per share was extended to May 9, 2026.
• The company believes it achieved the Term D Milestone from its PIK3CA wild-type cohort of Phase 3 VIKTORIA-1 clinical trial, making it eligible for an additional $30.0 million under the Term D Loan.
• The company intends to draw down the $30.0 million Term D Loan in late August 2025, before the August 31, 2025 expiration of the draw period.
• Preliminary cash, cash equivalents, and short-term investments are expected to be approximately $168.4 million as of June 30, 2025, down from $283.1 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. While the company is successfully securing significant capital, which is positive for funding its clinical pipeline, the substantial decrease in cash reserves over the past year and the necessity of such a large raise indicate a high burn rate. The extension of the conversion right for Innovatus also introduces potential future dilution. The overall sentiment is neutral to slightly negative, as the capital raise addresses a clear need but highlights the ongoing financial demands of a clinical-stage biotech.

Positives

• Eligibility to incur an additional $30.0 million under the Term D Loan due to achieving the Term D Milestone from the PIK3CA wild-type cohort of Phase 3 VIKTORIA-1 clinical trial.
• The proposed capital raise of $225.0 million (plus potential over-allotment options) is intended to fund working capital, general corporate purposes, clinical trial expenditures, commercial launch expenditures, research and development, capital expenditures, and business development.
• Capped call transactions are expected to reduce potential dilution from convertible notes and/or offset cash payments in excess of principal.

Negatives

• Preliminary cash, cash equivalents, and short-term investments decreased to $168.4 million as of June 30, 2025, from $283.1 million as of June 30, 2024, indicating significant cash burn over the past year.
• The company is raising substantial capital, which could indicate a need for funds beyond current operations or a strategic decision to bolster liquidity, but also suggests ongoing operational expenses.
• The extension of Innovatus's right to convert up to 20% of the Term A Loan into common stock at $10.00 per share until May 9, 2026, represents potential future dilution at a fixed price.

Risks

• The proposed offering may be delayed or terminated prior to completion.
• The company may fail to draw the Term D Loan on or before the expiration of the Term D Draw Period (August 31, 2025).
• The company or its independent registered public accounting firm may identify unexpected adjustments that would change the preliminary financial information disclosed.
• The company has a limited operating history.
• Potential inability to develop, validate, and commercialize gedatolisib on a timely basis or at all.
• The uncertainties and costs associated with clinical studies and with developing and commercializing biopharmaceuticals.
• The complexity and difficulty of demonstrating the safety and sufficient magnitude of benefit to support regulatory approval of gedatolisib and other products the company may develop.
• Challenges the company may face in developing and maintaining relationships with pharmaceutical company partners.
• The uncertainty regarding market acceptance by physicians, patients, third-party payors and others in the medical community, and with the size of market opportunities available to the company.
• Difficulties the company may face in managing growth, such as hiring and retaining a qualified sales force and attracting and retaining key personnel.
• Changes in government regulations.
• Tightening credit markets and limitations on access to capital.
• Stock market volatility or other factors that may affect the company's ability to access capital on favorable terms or at all.
• Obtaining and maintaining intellectual property protection for the company's technology and time and expense associated with defending third-party claims of intellectual property infringement, investigations or litigation threatened or initiated against the company.
• Activity by option counterparties in connection with hedging capped call transactions could increase or decrease the market price of the common stock or convertible notes.

Future Outlook

The company expects to complete its interim financial statements for the three and six months ended June 30, 2025, subsequent to the completion of the proposed offerings. It intends to draw down the $30.0 million Term D Loan in late August 2025. The offerings are subject to market and other conditions, with no assurance as to completion or final terms.

Management Comments

• "The Company believes that it has achieved the Term D Milestone (as defined in the A&R Loan Agreement) and therefore is eligible to incur an additional $30.0 million of indebtedness under the Term D Loan."
• "The Company intends to draw down such $30.0 million in late August 2025 prior to the expiration of the Term D Draw Period on August 31, 2025."

Industry Context

Celcuity is a clinical-stage biotechnology company focused on oncology, specifically developing targeted therapies for solid tumors. The capital raise and debt draw are typical for biotech companies in the clinical trial phase, which require significant funding for research, development, and clinical expenditures, especially for Phase 3 trials like VIKTORIA-1 and VIKTORIA-2 for breast cancer and CELC-G-201 for prostate cancer. The use of convertible notes and common stock offerings is a common financing strategy in the biotech sector to fund pipeline development and extend cash runway.

Comparison to Industry Standards

• The concurrent offering of convertible notes and common stock is a common financing strategy for clinical-stage biotech companies, similar to how companies like Relay Therapeutics or Blueprint Medicines have raised capital to fund their drug development pipelines.
• The use of capped call transactions is standard practice in convertible note offerings to mitigate dilution, a strategy employed by many growth-stage biotech firms to protect existing shareholder value.
• The significant cash burn, evidenced by the drop from $283.1 million to $168.4 million in cash, cash equivalents, and short-term investments over a year, is typical for a clinical-stage biotech company advancing multiple late-stage clinical trials (e.g., VIKTORIA-1, VIKTORIA-2, CELC-G-201), which are inherently capital-intensive. This burn rate is comparable to other companies with active Phase 3 programs, such as Mirati Therapeutics during its KRAZATI development or Seagen during its early commercialization efforts.
• The achievement of a "Term D Milestone" linked to clinical trial results (PIK3CA wild-type cohort of Phase 3 VIKTORIA-1) to unlock additional debt funding is a structured financing approach often seen in biotech debt facilities, providing capital upon specific R&D achievements, similar to milestones in venture debt agreements for companies like Crinetics Pharmaceuticals.

Corporate Governance

Related Party Transactions

• Innovatus Life Sciences Lending Fund I, LP, a lender, has its right to convert up to 20% of the outstanding principal of the Term A Loan into shares of the company's common stock at $10.00 per share extended to May 9, 2026.

Stakeholder Impact

• Shareholders: Potential dilution from the common stock offering and future conversion of convertible notes and Innovatus's Term A Loan. The capital raise aims to fund operations and clinical trials, which could ultimately benefit shareholders if successful. Capped call transactions are intended to reduce dilution.
• Creditors (Innovatus, Oxford Finance LLC): The loan agreement amendment allows for new convertible debt, potentially altering the company's capital structure and debt profile. Innovatus's conversion right extension provides continued flexibility for their investment.
• Employees: Continued funding for clinical trials and operations supports ongoing employment and potential growth opportunities.
• Patients: The capital raise directly supports the advancement of clinical trials for targeted cancer therapies (gedatolisib), potentially leading to new treatment options.

Next Steps

• Completion of the proposed concurrent offerings of Convertible Senior Notes and Common Stock.
• Completion of interim financial statements as of and for the three and six months ended June 30, 2025.
• Drawing down the $30.0 million Term D Loan in late August 2025.
• Option counterparties and/or their affiliates may enter into various derivative transactions and/or purchase/sell common stock to hedge capped call transactions.
• Ongoing enrollment in Phase 3 VIKTORIA-1 and VIKTORIA-2 clinical trials for HR+/HER2advanced breast cancer.
• Ongoing Phase 1/2 CELC-G-201 clinical trial for metastatic castration resistant prostate cancer.

Key Dates

Recommendation

The company is securing significant capital, which is crucial for a clinical-stage biotech with multiple ongoing trials. This financing addresses immediate liquidity needs and supports pipeline advancement. However, the substantial cash burn rate indicated by the preliminary financial results and the necessity of such a large capital raise suggest ongoing financial pressures. While the capital infusion is positive, the potential for future dilution from both the common stock offering and convertible notes, along with the extended conversion right for Innovatus, warrants a cautious approach. The stock is a "hold" as the capital raise provides stability for operations, but the long-term value depends heavily on successful clinical trial outcomes and commercialization, which remain uncertain and carry inherent biotech risks.

Keywords

Biotechnology, Oncology, Clinical-stage, Convertible Notes, Common Stock Offering, Capital Raise, Debt Amendment, Gedatolisib, PIK3CA, VIKTORIA-1, VIKTORIA-2, CELC-G-201, Breast Cancer, Prostate Cancer, Targeted Therapies, Nasdaq, CELC